These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 12227887)

  • 21. Links between hormone replacement therapy and neoplasia.
    Hulka BS
    Fertil Steril; 1994 Dec; 62(6 Suppl 2):168S-175S. PubMed ID: 7958013
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women.
    Stanford JL; Weiss NS; Voigt LF; Daling JR; Habel LA; Rossing MA
    JAMA; 1995 Jul; 274(2):137-42. PubMed ID: 7596001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast cancer risk in the WHI study: the problem of obesity.
    Kuhl H
    Maturitas; 2005 May; 51(1):83-97. PubMed ID: 15883113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progestins and breast cancer.
    Eden J
    Am J Obstet Gynecol; 2003 May; 188(5):1123-31. PubMed ID: 12748456
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Postmenopausal hormone therapy and the risk of breast cancer: a contrary thought.
    Speroff L
    Menopause; 2008; 15(2):393-400. PubMed ID: 17925662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hormone replacement therapy and breast cancer risk in Kyushu University Hospital: supporting the Women's Health Initiative study.
    Nozaki M; Koera K; Nagata H; Nakano H
    J Obstet Gynaecol Res; 2004 Aug; 30(4):297-302. PubMed ID: 15238106
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex steroids and breast cancer prevention.
    Spicer DV; Pike MC
    J Natl Cancer Inst Monogr; 1994; (16):139-47. PubMed ID: 7999456
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort.
    Persson I; Yuen J; Bergkvist L; Schairer C
    Int J Cancer; 1996 Jul; 67(3):327-32. PubMed ID: 8707404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of estrogen plus progestin on risk for biliary tract surgery in postmenopausal women with coronary artery disease. The Heart and Estrogen/progestin Replacement Study.
    Simon JA; Hunninghake DB; Agarwal SK; Lin F; Cauley JA; Ireland CC; Pickar JH
    Ann Intern Med; 2001 Oct; 135(7):493-501. PubMed ID: 11578152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement.
    Persson I; Weiderpass E; Bergkvist L; Bergström R; Schairer C
    Cancer Causes Control; 1999 Aug; 10(4):253-60. PubMed ID: 10482483
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.
    Ross RK; Paganini-Hill A; Wan PC; Pike MC
    J Natl Cancer Inst; 2000 Feb; 92(4):328-32. PubMed ID: 10675382
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hormone replacement therapy and risk of breast cancer: the role of progestins.
    Stahlberg C; Pedersen AT; Lynge E; Ottesen B
    Acta Obstet Gynecol Scand; 2003 Apr; 82(4):335-44. PubMed ID: 12716318
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progesterone receptors--animal models and cell signalling in breast cancer. Implications for breast cancer of inclusion of progestins in hormone replacement therapies.
    Schairer C
    Breast Cancer Res; 2002; 4(6):244-8. PubMed ID: 12473171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pregnancy, progesterone and progestins in relation to breast cancer risk.
    Campagnoli C; Abbà C; Ambroggio S; Peris C
    J Steroid Biochem Mol Biol; 2005 Dec; 97(5):441-50. PubMed ID: 16249080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estrogen, estrogen plus progestin therapy, and risk of breast cancer.
    Colditz GA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 2):909s-17s. PubMed ID: 15701886
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Post-menopausal breast cancer risk: oral estrogen treatment and abdominal obesity induce opposite changes in possibly important biological variables.
    Campagnoli C; Biglia N; Belforte P; Botta D; Pedrini E; Sismondi P
    Eur J Gynaecol Oncol; 1992; 13(2):139-54. PubMed ID: 1587291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women.
    Lacey JV; Brinton LA; Lubin JH; Sherman ME; Schatzkin A; Schairer C
    Cancer Epidemiol Biomarkers Prev; 2005 Jul; 14(7):1724-31. PubMed ID: 16030108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Postmenopausal hormone therapy: cardiovascular risks.
    Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancer.
    Birrell SN; Butler LM; Harris JM; Buchanan G; Tilley WD
    FASEB J; 2007 Aug; 21(10):2285-93. PubMed ID: 17413000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Body mass index and breast cancer risk according to postmenopausal estrogen-progestin use and hormone receptor status.
    Munsell MF; Sprague BL; Berry DA; Chisholm G; Trentham-Dietz A
    Epidemiol Rev; 2014; 36(1):114-36. PubMed ID: 24375928
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.